Charles River Laboratories International, Inc. (CRL)
- Previous Close
240.13 - Open
239.28 - Bid --
- Ask --
- Day's Range
237.44 - 244.56 - 52 Week Range
161.65 - 275.00 - Volume
655,765 - Avg. Volume
544,008 - Market Cap (intraday)
12.333B - Beta (5Y Monthly) 1.41
- PE Ratio (TTM)
25.97 - EPS (TTM)
9.22 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
270.80
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
www.criver.com20,400
Full Time Employees
December 30
Fiscal Year Ends
Sector
Industry
Recent News: CRL
Performance Overview: CRL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRL
Valuation Measures
Market Cap
12.33B
Enterprise Value
15.12B
Trailing P/E
25.97
Forward P/E
21.88
PEG Ratio (5yr expected)
1.86
Price/Sales (ttm)
2.98
Price/Book (mrq)
3.43
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
14.65
Financial Highlights
Profitability and Income Statement
Profit Margin
11.49%
Return on Assets (ttm)
5.19%
Return on Equity (ttm)
14.38%
Revenue (ttm)
4.13B
Net Income Avi to Common (ttm)
474.62M
Diluted EPS (ttm)
9.22
Balance Sheet and Cash Flow
Total Cash (mrq)
276.77M
Total Debt/Equity (mrq)
85.46%
Levered Free Cash Flow (ttm)
218.76M
Research Analysis: CRL
Company Insights: CRL
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CRL
Analyst Report: Charles River Laboratories Int
Charles River Laboratories is a non-clinical contract research organization (CRO), providing drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, and the Asia Pacific region. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The company is headquartered in Wilmington, Massachusetts.
RatingPrice TargetMarket Digest: BHP, ADBE, CRL, REG, RIO, VNT
Monday Tee Up: The Fed's Dot Plot
Analyst Report: Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice TargetAnalyst Report: Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target